We are live on ! Find out more
MNTA

Momenta Pharmaceuticals, Inc.
MNTA

Delisted

MNTA was delisted on the 30th of September, 2020.

133 hedge funds and large institutions have $730M invested in Momenta Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 39 increasing their positions, 48 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

85% more call options, than puts

Call options by funds: $17.9M | Put options by funds: $9.68M

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

23% more capital invested

Capital invested by funds: $591M → $730M (+$139M)

6% more funds holding

Funds holding: 126133 (+7)

19% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 48

Holders
133
Holders Change
+7
Holders Change %
+5.56%
% of All Funds
3.86%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
25
Increased
39
Reduced
48
Closed
18
Calls
$17.9M
Puts
$9.68M
Net Calls
+$8.22M
Net Calls Change
+$3.47M
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$65.4M -$43.7K -2,600 -0.1%
VAM
2
Visium Asset Management
New York
$64M +$47.4M +2,820,000 +353%
BFA
3
BlackRock Fund Advisors
California
$55.3M +$1.5M +89,313 +3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$54M +$1.95M +115,859 +4%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$51.7M -$289K -17,220 -0.6%
DCM
6
Discovery Capital Management
Connecticut
$34.1M
State Street
7
State Street
Massachusetts
$27.1M -$8.02M -477,500 -24%
Primecap Management
8
Primecap Management
California
$26.6M
BIT
9
BlackRock Institutional Trust
California
$24.8M -$393K -23,410 -2%
AllianceBernstein
10
AllianceBernstein
Tennessee
$21M -$801K -47,648 -4%
PAI
11
Palo Alto Investors
California
$20.5M +$346K +20,600 +2%
DM
12
Deerfield Management
New York
$20.1M -$14.6M -871,241 -43%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$18.5M -$931K -55,413 -5%
SAM
14
Sectoral Asset Management
Quebec, Canada
$15.8M +$716K +42,600 +5%
CCM
15
Camber Capital Management
Massachusetts
$14.1M
Northern Trust
16
Northern Trust
Illinois
$12.7M +$14.5K +860 +0.1%
Millennium Management
17
Millennium Management
New York
$11.5M +$2.7M +160,647 +33%
ACM
18
Apex Capital Management
Ohio
$10.7M +$10.1M +603,156 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$9.52M -$120K -7,170 -1%
BA
20
BlackRock Advisors
Delaware
$7.66M -$1.47M -87,673 -17%
Norges Bank
21
Norges Bank
Norway
$7.39M
Axa
22
Axa
France
$7.03M +$223K +13,253 +3%
VOYA Investment Management
23
VOYA Investment Management
Georgia
$6.73M -$42K -2,500 -0.7%
PC
24
PointState Capital
New York
$6.19M +$5.88M +350,000 New
Principal Financial Group
25
Principal Financial Group
Iowa
$4.94M +$148K +8,812 +3%

MNTA Hedge Fund Activity: Q4 2013 in Review

133 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q4 2013, worth a combined $730M — up 23% from $591M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new MNTA positions and 18 closed out — a net gain of 7 holders — while 39 added to existing stakes and 48 trimmed.

The largest buyer was Visium Asset Management, adding an estimated $47.4M. The largest seller was Bridger Management, exiting entirely with an estimated $24M sold.

  • 133 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q4 2013, up from 126 in Q3 2013.
  • Funds reported $730M of Momenta Pharmaceuticals, Inc. stock for Q4 2013, up 23% quarter-over-quarter.
  • 25 funds opened new Momenta Pharmaceuticals, Inc. positions in Q4 2013 and 18 closed out, a net change of +7 holders.
  • The largest Momenta Pharmaceuticals, Inc. buyer in Q4 2013 was Visium Asset Management, an estimated $47.4M added.
  • The largest Momenta Pharmaceuticals, Inc. seller in Q4 2013 was Bridger Management, an estimated $24M sold.

Based on aggregated 13F filings for Q4 2013.